Skip to main content

Table 3 Antibiotics susceptibilities of ESBL positive enterobacteriaceae isolates

From: Mortality and its predictors among hospitalized patients with infections due to extended spectrum beta-lactamase (ESBL) Enterobacteriaceae in Malaysia: a retrospective observational study

Antibiotics Frequency (%)
Sensitive Intermediate Resistant
Ampicillin (n = 108) 0 (0.0) 0 (0.0) 108 (100.0)
Amoxicillin (n = 100) 0 (0.0) 0 (0.0) 14 (100.0)
Piperacillin–tazobactam (n = 61) 24 (39.3) 19 (31.1) 18 (29.5)
Amoxicillin-clavulanate (n = 79) 1 (1.3) 19 (24.1) 59 (74.7)
Ampicillin-sulbactam (n = 21) 0 (0.0) 2 (9.5) 19 (90.5)
Cefuroxime (n = 109) 0 (0.0) 0 (0.0) 109 (100.0)
Ceftazidime (n = 89) 0 (0.0) 3 (3.4) 86 (96.6)
Ceftriaxone (n = 56) 0 (0.0) 0 (0.0) 56 (100.0)
Cefotaxime (n = 106) 0 (0.0) 0 (0.0) 106 (100.0)
Cefepime (n = 90) 0 (0.0) 4 (4.4) 86 (95.6)
Gentamicin (n = 69) 18 (26.1) 2 (2.9) 49 (71.0)
Imipenem (n = 107) 106 (99.1) 0 (0.0) 1 (0.9)
Meropenem (n = 107) 106 (99.1) 1 (0.9) 0 (0.0)
Ertapenem (n = 104) 103 (99.0) 0 (0.0) 1 (1.0)
Ciprofloxacin (n = 79) 7 (8.9) 19 (24.1) 53 (67.1)
Cotrimoxazole (n = 90) 14 (15.6) 0 (0.0) 76 (84.4)
Nitrofurantoin (n = 9) 0 (0.0) 1 (11.1) 8 (88.9)